The team behind Saltikva®.
Salspera is privately held and privately funded. We work with expert consultants in clinical trial monitoring, regulatory affairs and trial design.
Co-founders
Has founded or co-founded ten biotech companies over thirty years. PhD in organic chemistry and biotechnology, ETH Zürich.
Eddie Moradian is a co-founder of Salspera and serves as its Chief Executive Officer. A seasoned biotechnology executive, he has founded or co-founded 10 biotech companies over the past 30 years and is an experienced investor and operational chief executive in life-science research and early-stage drug development. Since 2004 he has served as CEO of MD Biosciences Innovalora Ltd., a contract research organization serving early-stage biotechnology companies. He also serves as CEO of Morwell Holding AG and as a partner of MD Bioproducts GmbH and MD Doctors Direct GmbH. He holds an M.Sc. in Biotechnology and a Ph.D. in Organic Chemistry/Biotechnology from ETH Zürich.
Originator of the platform. Professor of Surgery and Pediatrics, University of Minnesota. 23 patents, more than 160 publications.
Daniel Saltzman is a co-founder of Salspera, serves as its Chief Medical Officer, and originated the company’s technology platform. He is Professor of Surgery and Pediatrics and the A.S. Leonard Endowed Chair in Pediatric Surgery at the University of Minnesota Medical School, where he served as Chief of the Division of Pediatric Surgery; he recently retired from clinical practice. Internationally recognized as a pioneer in bacterial-based cancer therapy, he co-authored the first peer-reviewed publication demonstrating the use of Salmonella as a therapeutic platform in oncology and co-organized the 2017 NIH consensus conference “Bugs as Drugs: Microbial-Based Cancer Immunotherapy.” He holds 23 patents across 13 countries and has authored more than 160 scientific publications and 10 book chapters. He earned his B.S., M.D., and Ph.D. from the University of Minnesota and completed a fellowship in Pediatric Surgery at Arkansas Children’s Hospital.
Independent directors
UC Berkeley · co-founder, 4D Molecular Therapeutics
Professor of Chemical and Biomolecular Engineering, Bioengineering, and Molecular and Cell Biology at UC Berkeley and Director of QB3 and Bakar Labs. Over 250 publications and 50 issued patents; co-founder of 4D Molecular Therapeutics, Ignite Immunotherapies and Rewrite. Elected to the National Academy of Engineering and the National Academy of Inventors.
Former CFO, Lung Therapeutics and Recro Pharma
Two decades in life sciences and corporate finance. Formerly CFO of Lung Therapeutics and CFO, CBO and Treasurer of Recro Pharma. Earlier, a director in the Merchant Banking Group of Burrill & Company and nearly a decade in Healthcare Investment Banking at Deutsche Bank Securities. BBA, University of Michigan.
CFO, Avalon GloboCare · audit chair on several public boards
Chief Financial Officer of Avalon GloboCare Corp. and co-founder and former CFO of MagneGas Corporation. Serves as board member and Audit Committee Chair for several public companies. M.B.A. in Health, University of South Florida; B.S. in Finance, Boston University.
Scientific Advisory Board
Principal Investigator, ASCO TAPUR Study. Former Chief Medical Officer, American Society of Clinical Oncology.
Principal Investigator, ASCO TAPUR Study. Professor emeritus, University of Chicago. Former Chief Medical Officer, American Society of Clinical Oncology.
Chair, Department of Oncology, McGill University, Montreal, Canada
Chair, Department of Oncology, McGill University, Montreal, Canada. Director, Segal Cancer Center, Jewish General Hospital, Montreal.
Director, Novel Therapeutics Program, Mayo Clinic Cancer Center
Director, Novel Therapeutic Modality Program. Mayo Comprehensive Cancer Center, Mayo Clinic Scottsdale.
Global Head of Clinical Development, Healx
Global Head of Clinical Development, Healx. Kenneth and Betty Jane Dahlberg Emeritus Professor, University of Minnesota.
Director, O’Neal Comprehensive Cancer Center
Director, O’Neal Comprehensive Cancer Center. Evalina B. Spencer Chair in Cancer Biology. Director, O’Neal Cancer Service Line. University of Alabama at Birmingham.
Head, Pancreatic Cancer Center, Sheba Medical Center, Israel
Head, Pancreatic Cancer Center, Sheba Medical Center, Israel.